Can an Iron-Binding drug plus an antioxidant quiet Schizophrenia's 'Negative' symptoms?
Disease control
Not yet recruiting
This phase 2 trial tests whether adding a combination of deferiprone (an iron-chelating drug) and N-acetylcysteine (an antioxidant) to standard antipsychotic treatment can reduce the negative symptoms of schizophrenia, such as apathy, lack of motivation, and social withdrawal. Ab…
Phase: PHASE2 • Sponsor: Amit Lotan • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC